lutetium-177 lipiodol

Lutetium-177 lipiodol is a **radiopharmaceutical formulation** combining the beta- and gamma-emitting radionuclide **lutetium-177** with lipiodol for transarterial injection, primarily aimed at treating **hepatocellular carcinoma (HCC)**. Lipiodol, an oily contrast medium, selectively accumulates in HCC nodules after transarterial administration, acting both as an embolic agent and a vehicle for the radionuclide. Lutetium-177, with a **~6.7 day half-life**, emits beta particles to induce tumoricidal effects and gamma photons for SPECT imaging (theranostics). Compared to iodine-131 or rhenium-188 lipiodol, lutetium-177 offers an advantageous physical half-life, favorable imaging characteristics, and potential for more prolonged tumor irradiation, with reported preclinical evidence of tumor growth suppression, high tumor retention, and manageable toxicity. Clinical experience is limited, with most results in the preclinical or early translational phase[1][2].

Brand names

lutetium-177 lipiodollutetium177 lipiodollutetium 177 lipiodol

Other names

177Lu-lipiodol^177Lu-lipiodollutetium 177-lipiodollutetium177-lipiodollutetium-177-lipiodolradiolabeled lipiodol with lutetium-177